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Summary
Objective: Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are widely used in the treatment of osteoarthritis (OA). For the outcome of treatment
the direct effects of NSAIDs on cartilage may be more important than indirect effects on inﬂammation, considered being secondary in OA. For
clinical practice, it is relevant to study effects of NSAIDs on early stages of OA. Therefore we studied the direct effects of celecoxib on human
degenerated OA cartilage and compared the effects with those on human healthy cartilage and human end-stage OA cartilage.
Methods: Degenerated, late-stage OA, and healthy human articular cartilage were exposed (7 days of culture) to celecoxib (0.1e10 mM).
Changes in cartilage proteoglycan turnover (synthesis, retention, and release), proteoglycan content, prostaglandin E2 (PGE2) and nitric oxide
(NO) production were determined.
Results: Both degenerated and established OA cartilage showed its characteristic changes in proteoglycan turnover (all P! 0.05). Celecoxib
at 1 mM was able to increase synthesis of degenerated cartilage and normalize both releases of newly formed and resident proteoglycans.
Importantly, 1 mM celecoxib inﬂuenced matrix integrity by enhancing proteoglycan content. Similar results were found for end-stage OA
cartilage. Enhanced PGE2 production in degenerative and OA cartilage could be decreased by celecoxib, whereas no effect on enhanced NO
production was found. No signiﬁcant effects of celecoxib on normal cartilage were found.
Discussion: Celecoxib, in a clinical relevant concentration, showed in vitro a signiﬁcant beneﬁcial effect, not only on late-stage OA but also on
more early stages of OA, whereas healthy cartilage remained unaffected, suggesting chondroprotective properties of celecoxib in the
treatment of degenerative joint disorders.
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In osteoarthritis (OA) damage to cartilage is characterized
by loss of matrix proteoglycans and damage of the collagen
structure. Although OA is primarily an intrinsic process of
the cartilage, secondary synovitis may trigger clinical
symptoms and add to the ﬁnal damage of the cartilage
tissue and with that to joint damage in general1e3.
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) diminish
inﬂammation, therefore NSAIDs may indirectly be beneﬁcial
to cartilage under inﬂammatory conditions although this has
never been proven in clinical trials. Based on in vitro and
animal studies, direct effects of NSAIDs on cartilage have
frequently been reported4e7. Although different experimen-
tal setups have been used in different studies these studies
clearly show that some of the used NSAIDs have direct
adverse effects on cartilage, though beneﬁcial and neutral
effects have been reported as well5e8. These direct effects
cannot be studied easily in clinical trials and therefore they
are generally ignored in clinical practice. This is because
these direct effects on cartilage are shaded by the effects of
NSAIDs on inﬂammation and because (intrinsic) cartilage
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Received 19 August 2004; revision accepted 6 February 2005.51changes, catabolic and anabolic, are generally very slow
processes in OA.
Direct effects of NSAIDs on cartilage may be important
speciﬁcally in long-term treatment of joint disease in which
inﬂammation is only mild and secondary as in OA. Thus,
although NSAIDs may be very useful in reducing pain and
inﬂammation in OA, when their direct effects are adverse,
they may contribute to the process of cartilage degeneration
by interfering with the intrinsic repair activity.
The anti-inﬂammatory effects of NSAIDs are mainly due to
their ability to inhibit prostaglandin production by cyclo-
oxygenase (COX) in a non-speciﬁc manner, thereby dem-
onstrating efﬁcacy but also toxicity9e11. The discovery of two
isoforms of COX, COX-1 and COX-2, provided insight into
the mechanism of action and toxicity of NSAIDs. Much has
been learned about these isoenzymes since their discovery.
The discovery of COX-2 has spurred the development of
drugs that could selectively inhibit COX-2, lacking the
adverse effects of traditional NSAIDs. Celecoxib, as one of
the ﬁrst selective COX-2 inhibitors, has been shown to be an
effective anti-inﬂammatory and analgesic drug in patients
with rheumatoid arthritis and OA, comparable to that of
traditional NSAIDs, such as naproxen, diclofenac and
ibuprofen12e14. A signiﬁcant reduction of gastrointestinal
adverse events with selective COX-2 inhibitors compared to
non-selective NSAIDS has been demonstrated frequently.
In the treatment of OA, as explained above, it remains at
least as important to know the direct effects of these drugs
on cartilage. This is speciﬁcally important because COX-2
is found to be expressed in OA tissues15,16. Both in9
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of COX-2 have been found. Also elevated levels of
prostaglandin E2 (PGE2) have been found in OA cartilage,
indirectly demonstrating a role for COX-2 in diseased
cartilage17. Most recently, the expression of COX-2 and
PGE2 in OA meniscus, synovial membrane, osteophytic
ﬁbrocartilage and in the articular OA cartilage has been
described15. Furthermore, the latter study showed an
increased proteoglycan degradation that correlated with
COX-2 protein expression and PGE2 production by the
synovial membrane. In a previous study of our group we
showed a beneﬁcial effect of COX-2 inhibition in interleukin-
1 (IL-1) and tumor necrosis factor-a (TNFa) treated
cartilage18. Because these mediators play a role in cartilage
damage in OA, this ﬁnding indirectly indicates a possible
role of COX-2, in the process of cartilage degeneration and
the attempt to repair, as seen in OA. Recent ﬁndings by El
Hajjaji et al.19 showed that celecoxib was able to increase
proteoglycan synthesis and was able to diminish pro-
teoglycan release of OA cartilage obtained at joint re-
placement surgery. However, this cartilage represents an
end-stage of OA, the result of degeneration and repair that
has taken place over many years. For the treatment of OA
in clinical practice, it is more relevant to evaluate more early
stages of cartilage degeneration. Moreover, in addition to
knowledge on proteoglycan turnover (synthesis and re-
lease) it is also important whether this beneﬁcial effect on
turnover results in actual improvement of matrix integrity as
indicated by an increase in proteoglycan content that is
signiﬁcantly diminished in the case of OA.
For this reason, the present study evaluates the in vitro
effect of celecoxib on human articular cartilage. Effects on
degenerated (pre-clinical) OA cartilage were compared to
those on established (end stage) OA and healthy cartilage.
Material and methods
CARTILAGE CULTURE TECHNIQUE
Normal healthy cartilage based on a smooth glossy
appearance was obtained post mortem from patients
without history of joint disorders (mean age 69G 5 years
(GS.E.M.), two males, four females). Degenerated articular
cartilage tissue that was obtained post mortem as well
(mean age 80G 3 years (GS.E.M.), two males, two
females). Degenerated cartilage was identiﬁed macroscop-
ically on the bases of a ﬁbrillated surface as previously
reported20. Also, these donors had no clinical history on
joint disorders. This stresses the difference between
degenerative changes in cartilage that could have been
visualized by radiography and actual clinical manifestations
of the disease which may result in the diagnosis of OA. In
general, all changes observed in degenerated cartilage are,
although less pronounced, observed in osteoarthritic (OA)
cartilage and are signiﬁcantly different from normal healthy
cartilage. For that reason degenerated cartilage obtained
post mortem can be considered as a pre-clinical phase of
OA20. OA cartilage obtained from patients at knee re-
placement surgery with diagnosed OA (mean age 69G 2
years (GS.E.M.), one male, ﬁve females) was obtained post-
operatively. NSAID medication is stopped 7 days before
surgery, thus no interference of previous medication use is
to be expected. It should be kept in mind that only the
cartilage that could be cut from the deteriorated joints (after
replacement surgery) was used. Cartilage that appeared
with full thickness with signiﬁcant ﬁbrillation was selected.
Thus in fact the entire joint had a worse appearance thanrepresented by the cartilage used for evaluation. Mostly
signiﬁcant parts of the joint were only covered with thin or
sometimes no cartilage. OA cartilage obtained at joint
replacement surgery represents an end stage of OA that
reﬂects degenerated as well as reparative processes and in
that respect differs from degenerated cartilage although the
histological classiﬁcation may be comparable. Cartilage
obtained post mortem was taken within 24 h of death from
human knee condyles, cartilage obtained post-surgery
always within 4 h after dissection. Collection of cartilage
was according to the medical ethical regulations of the
University Medical Center Utrecht. Slices of cartilage were
cut aseptically as thick as possible from the articular surface,
excluding the underlying bone, and kept in phosphate
buffered saline (PBS). Within 1 h of dissection the slices
were cut into square pieces, weighed aseptically (range
5e15 mg, accuracy G0.1 mg) and cultured individually in
96-well round-bottomed microtiter plates (200 ml culture
medium, 5% CO2 in air, 37(C). The culture medium
consisted of Dulbecco’s modiﬁed Eagle’s medium (DMEM),
supplemented with glutamine (2 mM), penicillin (100 IU/ml),
streptomycin sulfate (100 mg/ml), ascorbic acid (0,085 mM),
and 10% heat inactivated pooled human male ABC serum.
Cartilage was always pre-cultured for 24 h (wash-out
period), after which culture medium was refreshed before
start of the experiment. In addition, three tissue samples of
each donor were ﬁxed in 4% phosphate buffered formalin for
standard light microscopy. Sections were stained with
safranin-O fast green-iron hematoxylin and graded for
features of OA according to the slightly modiﬁed criteria21
described by Mankin. The tidemark between cartilage and
bone was not present in our cartilage samples since bone
was not included. Also as a result of our dissection method,
cartilage samples were not covered with pannus. Therefore,
the maximum score that could be obtained was 11 instead of
the original 14, when all criteria described by Mankin et al.22
(including pannus, clefts to calciﬁed zone, and tidemark
crossed by blood vessels) could have been included.
EXPERIMENTAL SETUP
Healthy, early and late OA human articular cartilage
tissues were cultured for 7 days. Celecoxib (supplied by
Pﬁzer USA) was added at the start of the culture in
concentrations of 0.1, 1 and 10 mM. The mean pharmaco-
logical plasma concentration was 5 mM23. After 4 days
medium was refreshed and cartilage cultured for a succes-
sive 3 days with the same additions. Changes in cartilage
matrix turnover (proteoglycan synthesis, retention, and
release) and matrix integrity (proteoglycan content) were
determined. Experiments were repeated at least 4 times; for
each experiment, cartilage of another donor was used.
PROTEOGLYCAN ANALYSES
Sulphate incorporation rate was determined, as a mea-
sure of the proteoglycan synthesis rate, during the last 4 h
of the ﬁrst 4-day culture period, as described previously24.
Before addition of 35SO4
2 (Na2
35SO4, 14.8 kBq/200 ml,
DuPont NEX-041-H, carrier-free), culture medium was
replaced by equilibrated (CO2 and temperature) fresh
medium. After 4 h labeling, the cartilage explants were
rinsed 3 times for 45 min in culture medium under culture
conditions and incubated for the additional period of 3 days.
After this second culture period medium was removed and
stored at 20(C for further analysis. Cartilage tissue
samples were digested (2 h, 65(C) in papain buffer as
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appropriate concentrations and glycosaminoglycans
(GAGs) were stained and precipitated with Alcian Blue
dye solution26. The pellet obtained after centrifugation
(9000g, 10 min) was washed once (NaAc-buffer containing
0.1 M MgCl2) and subsequently dissolved in sodium
dodecyl sulfate (SDS). The 35SO4
2 radioactivity of the
samples was measured by liquid scintillation analysis.
35SO4
2 incorporation was normalized to the speciﬁc activity
of the medium, labeling time and wet weight of the cartilage
samples, and proteoglycan synthesis rate expressed as
nanomoles sulfate incorporated per hour per gram wet
weight of the cartilage (nmol/h/g).
Release of newly formed proteoglycans as a measure of
retention of these proteoglycans was determined similarly.
GAGs were precipitated from the medium obtained from
day 4 to 7 and stained with Alcian Blue dye solution27. The
radio-labeled GAGs were measured by liquid scintillation
analysis and normalized to the proteoglycan synthesis rate
and expressed as percentage release of newly formed
proteoglycans.
For the total release of proteoglycans, the GAG in the
medium obtained from days 4 to 7 were precipitated and
stained with Alcian Blue as described above24. The GAG
content in the papain digest of cartilage samples, as
a measure of proteoglycan content, was analyzed the same
way. Blue staining was quantiﬁed photometrically by the
change in absorbance at 620 nm. Chondroitin sulfate (Sigma
C4383) was used as a reference. Values for content were
normalized to the wet weight of the cartilage and expressed
as milligram of GAG/gram wet weight of cartilage (mg/g).
Values for release were normalized to the GAG content of
the explants and expressed as percentage release of GAGs.
PGE2 AND NITRIC OXIDE (NO) DETERMINATION
PGE2 was determined in culture medium at day 4 by
Enzyme Immuno Assay (EIA, Caymann Chemical) and
expressed in pg/ml. Nitrite and nitrate concentration (as
a measure for NO) in the same culture medium of the ﬁrst 4
days of culture was quantiﬁed by colorimetric assay based
on the Griess reaction and expressed in micromolar.
CALCULATIONS AND STATISTICAL ANALYSIS
Because of focal differences in composition and bio-
activity of the cartilage on the femur condyles, the results of
10 cartilage samples per parameter per donor, obtained
randomly and handled individually, were averaged and
taken as a representative value for the cartilage of that
donor. Several experiments with each cartilage of a different
donor (at least nZ 4) were performed. Statistical evaluation
of differences between healthy, degenerated and OA
cartilage was performed with a non-parametric test for
unpaired data (ManneWhitney). Statistical evaluation of the
effects of treatment was performed with a non-parametric
test for paired data (Wilcoxon). P values less than or equal
to 0.05 were considered statistically signiﬁcant.
Results
THE EFFECT OF CELECOXIB ON NORMAL CARTILAGE
Average Mankin grade of the normal cartilage,
as expected, was low; 1G 0.1 on a scale of 11. The
cartilage had always an intact articular surface, safranin-O
staining was equally distributed throughout the tissue andchondrocyte localization showed a normal appearance
[Fig. 1(A) and Table I].
Celecoxib, at a concentration of 10 mM, did not change
proteoglycan turnover of normal healthy human articular
cartilage [dotted lines in Fig. 2(AeD)]; proteoglycan
synthesis rate [Fig. 2(A)], percentage release of newly
formed proteoglycans [Fig. 2(B)], as a measure of retention
of these newly formed proteoglycans, and the percentage
release of proteoglycans [resident ones plus newly formed,
Fig. 2(C)] did not change. Also GAG content [Fig. 2(D)] was
not inﬂuenced signiﬁcantly by celecoxib. When release of
newly formed and total amount of proteoglycans were
calculated as absolute values, not normalized to synthesis
rate and content, respectively, also no effects of celecoxib
on normal cartilage were found (data not shown). Also at
a concentration of 0.1 and 1 mM no effects were found as
reported previously18.
EFFECTS OF CELECOXIB ON DEGENERATED
(PRE-CLINICAL OA) CARTILAGE
Mostly treatment with NSAIDs will take place on early
stages of joint degeneration. Therefore, we tested celecoxib
on degenerated (pre-clinical OA) cartilage. The degenerated
cartilage had on average a modiﬁed Mankin score of 4G 0.5
(Table I). In the degenerated tissue, surface deterioration
was visible. The safranin-O staining was lost from the
surface layer of the degenerated samples and chondrocyte
distribution was disturbed [Fig. 1(B)]. The early OA cartilage
showed the typical intermediate biochemical features with
respect to proteoglycan turnover when compared to healthy
human cartilage and OA cartilage (Table I)20.
When degenerated cartilage was incubated with cele-
coxib, in a concentration of 0.1e10 mM, a slight but dose-
dependent increase of the cartilage matrix synthesis was
observed [Fig. 2(A) squares] at all concentrations tested
statistically signiﬁcant compared to untreated control
degenerated cartilage. The actual synthesis rate reached
even higher levels than normal cartilage although not
statistically signiﬁcant.
Release of newly formed proteoglycans, as absolute
values (data not shown) and as percentage (normalized to
the proteoglycan synthesis rate) was signiﬁcantly reduced
up to nearly complete normalization by the addition of
celecoxib [at all concentrations tested statistically signiﬁ-
cant; Fig. 2(B) squares]. Although there appeared to be
a slight dose dependency, statistically, normalization was
reached already at the lowest concentration tested.
Similar results were found for the release of all
proteoglycans, newly formed plus resident proteoglycans,
when calculated as absolute (data not shown) and
normalized to the proteoglycan content representing per-
centage total proteoglycan release [Fig. 2(C) squares].
Again we found a reduction up to complete normalization
under the inﬂuence of celecoxib. Already at the lowest
concentration used, the addition of celecoxib resulted in
a retention of newly formed proteoglycans not different from
normal healthy cartilage anymore.
With respect to matrix integrity celecoxib was able to
induce normalization in proteoglycan content [Fig. 2(D)
squares] that was statistically signiﬁcant at all concentra-
tions tested.
EFFECTS OF CELECOXIB ON OA CARTILAGE
The OA cartilage had on average a modiﬁed Mankin
score of 5G 0.5, slightly higher than that of degenerative
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mortem from joints with normal healthy cartilage (A), or joints with degenerated cartilage (B) and cartilage obtained at joint replacement
surgery (C). Sections are stained with safranin-O fast green-iron hematoxylin and graded for features of OA according to the slightly modiﬁed
criteria described by Mankin et al., scores for the depicted samples are 0, 4 and 6, respectively.cartilage (Table I) and signiﬁcantly higher than that of
normal cartilage. It should be kept in mind that only the
cartilage that could be cut from the joint surfaces after
replacement surgery was used. Thus in fact the entire joint
had a worse appearance than represented by the modiﬁed
Mankin score of the cartilage used. The OA cartilage
surface deterioration was clearly visible by light microscopy.The safranin-O staining was lost from the surface layer of
the degenerated samples and chondrocyte distribution was
disturbed [clusters of chondrocytes in the surface layer of
the cartilage were visible; Fig. 1(C)]. The OA cartilage
showed the typical biochemical features with respect to
proteoglycan turnover when compared to healthy human
cartilage (Table I) and these changes always exceeded theTable I
The histological and biochemical characteristics of human healthy cartilage, degenerative and osteoarthritic cartilage
Normal cartilage
(averageG S.E.M.; nZ 4)
Degenerative cartilage
(averageG S.E.M.; nZ 4)
P! OA cartilage
(averageG S.E.M.; nZ 6)
P!
Histological cartilage damage 1G 0.1 4G 0.5 0.05 5G 0.5 0.05
PG synthesis (nmol/h/g) 10G 1 8G 3 ns 5G 2 0.05
% New release (%) 6G 1 8G 1 0.01 11G 1 0.01
% Total
release (%)
3G 1 5G 1 0.03 6G 1 0.02
PG-content (mg/g) 35G 2 23G 5 0.03 18G 3 0.01
Prostaglandin E2 (pg/ml) 64G 9 129G 12 0.03 215G 34 0.03
Nitric oxide (mM) 2.9G 0.3 4.3G 1.1 ns 8.0G 1.6 0.05
Proteoglycan synthesis rate as a measure of cartilage matrix synthesis, percentage release of newly formed proteoglycans as a measure of
retention for the newly formed proteoglycans (normalized to the synthesis of these proteoglycans), percentage total release of proteoglycans,
calculated by the percentage release of GAG (normalized to the GAG content), proteoglycan content, PGE2 and NO. The results are
presented as means of at least four experiments (viz. four cartilage donors) GS.E.M.. Statistical evaluation of differences between healthy
human articular cartilage and degenerated or OA cartilage was performed with a non-parametric test for unpaired data. P values less than or
equal to 0.05 were considered statistically signiﬁcant.
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Fig. 2. The effect of celecoxib on degenerated and OA human articular cartilage explants. Proteoglycan synthesis rate as measure of cartilage
matrix synthesis (A), percentage release of newly formed proteoglycans (B) as a measure of retention for the newly formed proteoglycans
(normalized to the synthesis of these proteoglycans), percentage total release of proteoglycans (C), measured by the percentage release of
GAG (normalized to the GAG content), and proteoglycan content (D) are depicted. Diamonds represent effects of celecoxib (only 10 mM) on
normal cartilage, squares represent effects of celecoxib on degenerated cartilage, and dots represent effects of celecoxib on OA cartilage. The
results are presented as means of at least four experiments with each cartilage of a different donorGS.E.M. Statistically differences between
degenerated and OA cartilage compared to normal cartilage, calculated by non-parametric unpaired analysis (P! 0.05) at baseline are
marked with an #. Statistically differences of the effects of celecoxib compared to controls, calculated by non-parametric paired analysis
(P! 0.05) are marked with an asterisk.changes as observed in degenerated cartilage. The effects
of celecoxib, observed for late-stage OA cartilage, were
similar as for degenerative OA cartilage [Fig. 2(AeD)].
For all proteoglycan parameters there was a statistically
signiﬁcant improvement found when celecoxib was added.
However, both proteoglycan synthesis rate and proteogly-
can content remained statistically signiﬁcant below healthy
cartilage control values. None of the effects of celecoxib on
OA cartilage were statistically signiﬁcantly different from the
effects on degenerated cartilage.
EFFECT OF CELECOXIB ON PGE2 AND NO PRODUCTION
In addition to proteoglycan turnover and content, we have
determined the effect of celecoxib on PGE2 production as
a indirect measurement of COX-2 activity. To demonstrate
that the effects of celecoxib were COX-2 (viz. PGE2) related
we also quantiﬁed the NO production of the different types
of cartilage.
In both degenerated and OA cartilage the amount of
PGE2 formed and measured in the supernatant of thecartilage cultures was signiﬁcantly elevated compared to
normal cartilage (Table I). OA cartilage showed the highest
amounts of PGE2, most likely due to the strongest COX-2
activity, where the basal level of normal cartilage is most
likely due to non or low COX-2 activity.
Similar results were found for the NO levels (Table I). In
both types of diseased cartilage NO was elevated (on
average 2.9G 0.3 mM, 4.3G 1.1 mM, and 8.0G 1.6 mM for
normal, degenerated, and clinicalOAcartilage, respectively),
again with the highest levels found in the OA cartilage.
The basal PGE2 production of normal cartilage was not
inﬂuenced by celecoxib at a concentration of 10 mM (Fig. 3,
open bars). In contrast, when degenerated cartilage was
incubated with celecoxib, normalization of the elevated
PGE2 levels occurred in a dose-dependent manner (Fig. 3
gray bars). Also the elevated PGE2 levels of OA cartilage
could be normalized, in a dose-dependent manner, when
incubated with celecoxib (Fig. 3, black bars). The normal-
ization of PGE2 production in both degenerated and OA
cartilage shows indirectly that celecoxib inhibits COX-2
activity in degenerative and OA cartilage.
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Fig. 3. The effect of celecoxib on PGE2 of normal, degenerated and OA human articular cartilage explants. PGE2 production of normal,
degenerated, and OA cartilage with or without celecoxib are depicted. Open bars represent effects of celecoxib on normal cartilage, gray bars
represent effects of celecoxib on degenerated cartilage, and black bars represent effects of celecoxib on OA cartilage. The results are
presented as means of at least four experiments with each cartilage of a different donorGS.E.M. Statistically differences between degenerated
and OA cartilage compared to normal cartilage, calculated by non-parametric unpaired analysis (P! 0.05) at baseline are marked with an
asterisk. Statistically differences of the effects of celecoxib compared to untreated controls, calculated by non-parametric paired analysis
(P! 0.05) are marked with a triangle.In contrast to PGE2, the NO production of normal,
degenerated and OA cartilage was not inﬂuenced by
celecoxib (on average 3.1G 0.9 mM, 4.3G 2.5 mM and
7.0G 1.5 mM for normal, degenerated and clinical OA
cartilage incubated with 10 mM celecoxib, respectively).
Discussion
Our study shows that the selective COX-2 inhibitor
celecoxib has a favorable effect on proteoglycan synthesis,
retention, release and content of both degenerated (pre-
clinical) and (late-stage) OA cartilage. On normal healthy
cartilage no effects were observed, conﬁrming our previous
results18 where we showed in a complete dose response
curve that normal cartilage remained unaffected. Our
results with respect to proteoglycan synthesis and retention
of late-stage OA cartilage corroborate recent ﬁndings by El
Hajjaji et al.19 using a slightly different approach. In their
study, they also demonstrated a beneﬁcial effect on
hyaluronan synthesis in human late-stage OA cartilage
obtained at joint replacement surgery. The present study
adds in this respect that release of resident proteoglycans
also and more importantly, proteoglycan content is bene-
ﬁcially inﬂuenced by celecoxib. In addition, our study shows
that also for degenerated cartilage a chondroprotective
effect of celecoxib can be observed.
All beneﬁcial effects on cartilage proteoglycan turnover
and content were similar for OA cartilage obtained at joint
replacement surgery and degenerated (pre-clinical) carti-
lage. However, especially degenerated cartilage seems to
proﬁt from COX-2 inhibition as all four parameters
normalized whereas for OA cartilage COX-2 inhibition
normalized only retention and release. This, and the fact
that normal healthy cartilage stays unaffected is of major
importance in the treatment of patients with OA. This could
mean that treatment of OA patients with celecoxib
speciﬁcally at an early stage of their disease could
slowdown further damage and with that postpone furtherinvasive chirurgical treatment (joint replacement surgery).
These effects contrast the results of several other studies
obtained with NSAIDs tested under comparable conditions.
Frequently used NSAIDs such as naproxen and ibuprofen
have been demonstrated to inhibit the synthesis of cartilage
proteoglycans4,5,8,27 and to increase the release of proteo-
glycans27. However, although mostly effects have been
reported to be adverse, also no or positive effects of
NSAIDs have been described4,5,8,27,28.
These are all direct effects on cartilage and should be
seen in the context of the signiﬁcant anti-inﬂammatory
effects of these NSAIDs. By inhibiting joint inﬂammation
they may indirectly be beneﬁcial to cartilage, speciﬁcally
when inﬂammation is primary in the cause of cartilage
damage as, e.g., in rheumatoid arthritis. In the case of OA,
where inﬂammation may contribute but is not primarily
responsible for cartilage damage, adverse direct effects of
NSAIDs on cartilage during long-term treatment may have
important impact on long-term outcome.
This study describes a beneﬁcial effect of a selective
COX-2 inhibitor on OA cartilage proteoglycan turnover and
content, whereas no effects are observed on normal healthy
cartilage. This could be due to better accessibility of
celecoxib in (pre-clinical) OA cartilage, due to its ﬁbrillated
surface. However, in a previous study18 we showed that
healthy cartilage with an intact surface, when co-cultured
with peripheral blood mononuclear cells of rheumatoid
arthritis patients or with a combination of IL-1b and TNFa
demonstrated the same cellular characteristics, as OA
chondrocytes in the present study, which could be
normalized by the addition of celecoxib. This suggests that
the difference between normal and (pre-clinical) OA
cartilage is not due to accessibility. Furthermore, the
elevated PGE2 levels in degenerative and even more
elevated in OA cartilage (according to literature15,16), that
could be normalized by addition of celecoxib suggest COX-
2 regulation to be involved, rather than just accessibility.
Another important mediator of cartilage damage is NO. The
production of NO in joint pathology could contribute to
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NO on synovial cells and chondrocytes include: inhibition of
collagen and proteoglycan synthesis; activation of metal-
loproteinases; and apoptosis30. It appeared that celecoxib
was not able to inﬂuence the elevated NO production of
degenerative and OA cartilage in our study. This implies
that the favorable effect of celecoxib on (pre-clinical) OA
cartilage is mainly due to inhibiting COX-2 activity. The
remaining elevated levels of NO could explain why COX-2
inhibition does not normalize for both types of diseased
cartilage all proteoglycan parameters. Especially proteogly-
can synthesis seems to favor only partially from COX-2
inhibition. This ﬁts with the knowledge that high levels of NO
decrease PG synthesis30.
The presence of COX-2 in OA cartilage, directly mea-
sured15,16 or indirectly via PGE2
17, is evident. It could be,
although speculative, that the adverse affects of some of the
conventional NSAIDs on the cartilage results from inhibition
of COX-1, which could be essential for normal chondrocyte
function. However, other effects of these NSAIDs, COX
independent, might be involved as well9. The other way
around, whether selective COX-2 inhibitors, other than
celecoxib, are as beneﬁcial for (pre-clinical) OA cartilage
remains to be established as well. All the effects found in the
present study are beneﬁcial to cartilage. Moreover, the
response is obtained with a clinical relevant concentration of
the drug because the mean pharmacological plasma
concentration is 5 mM23. The response is also quick, within
7 days chondrocytes appear to be able to start restoration of
the extracellular matrix. Whether these promising effects
also take place in vivo remains of course to be seen. In vivo
animal studies and clinical trials have to be performed to
prove the suggestive chondroprotection of COX-2 inhibition
found in vitro. The present results imply an important role for
COX-2 in the disturbed proteoglycan turnover in OA, making
COX-2 inhibitors a relevant choice of treatment in the
elderly. On the other hand, questions have been raised
about cardiovascular side effects, and about possible
adverse effects on bone healing. These effects appear to
be shared with non-selective NSAIDs31e33.
In conclusion, although in vitro ﬁndings, the present study
suggests that besides the anti-inﬂammatory and analgesic
characteristics of selective COX-2 inhibitors, celecoxib has
cartilage protective capacities, contributing directly to
improvement of cartilage matrix integrity in OA already in
an early phase, which expectedly depends on its selective
COX-2 inhibition.
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